Prosolia DESI 2D™ Molecular Imaging Now Compatible with Agilent Technologies

July 20, 2017

DESI 2D increases potential applications when coupled with the precision of Agilent TOF, Q-TOF and IM-Q-TOF LC/MS systems.

href="https://prosolia.com">Prosolia, Inc., the exclusive manufacturer of DESI systems, introduced a new DESI 2D model compatible with Agilent TOF, Q-TOF and IM-Q-TOF LC/MS systems. With no sample prep required, DESI 2D enables molecular imaging without matrix by mass

ASMS 2017

January 27, 2017
Miss us at ASMS 2017? href="https://prosolia.com/asms-2017/">Click here to see what you missed and to discover how Prosolia is making mass spec better.

MSACL US 2017

January 20, 2017
See for yourself the exciting new developments in Molecular Imaging using Mass Spectrometry for uncovering disease pathology and novel drug screening methods for forensic toxicology. Miss the conference? href="https://prosolia.com/msacl/">Click here to get the recap!

Children remain underrepresented in drug research says Purdue expert, new tools can help

January 10, 2017
Children continue to be underrepresented in drug and medical research, making them less likely to receive personalized health-care treatments for life-threatening conditions such as cancer and infectious disease, says Purdue University professor of chemistry Peter Kissinger. New tools are about to change this.

Prosolia Named Indiana Company to Watch

August 26, 2016
President & CEO, Justin Wiseman, was awarded the honor at the Annual Companies to Watch Gala on August 25, 2016, at the Indiana Roof Ballroom in Indianapolis. Justin was accompanied by Director, Pete Kissinger, Director of Operations, Greg Lyons, and Sr. Business Manager, John Graves at the event. Congratulations to the Prosolia team for their

Prosolia Enters into Collaborative Research Agreement with University of Florida

April 5, 2016
“We are delighted to be working with the University of Florida, Professors Rick Yost and Tim Garrett on the development and application of our flowprobe technology for clinical research.” Said Justin Wiseman, President & CEO, Prosolia, Inc. | April 5, 2016